Mina Salib, MD
Interventional Pain Medicine · State College, PANPI 1346734142
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,791 of the $4,201 with a category attached, or 66.4%. 14 manufacturers reported payments, led by Boston Scientific at 52.6% of the total. Reporting peaked in 2024 at $2,112 and has fallen 79.9% since, to $424 in 2025.
Across 47 payments — averaging $89.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$1K
- SPR Therapeutics, Inc$371
- Abbott$131
- AbbVie$106
- Vertex$49
- plus $210 from 8 others
What the payments were for
- Travel & lodging$2,79166%
- Food & beverage$1,41034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $2,210 |
| Medtronic | 10 | $1,123 |
| SPR Therapeutics, Inc | 4 | $371 |
| Abbott | 4 | $131 |
| AbbVie | 5 | $106 |
| Vertex | 2 | $49 |
| Nevro Corp. | 1 | $37 |
| Stryker | 1 | $36 |
| Avanos Medical | 2 | $36 |
| Bioventus LLC | 2 | $33 |
| Relievant Medsystems, Inc. | 1 | $24 |
| Globus Medical | 1 | $16 |
| Pfizer | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$789
- SPRINT PNS System$295
- INTELLIS ADAPTIVESTIM$122
- SUPERION$100
How this compares
$4,201 in reported general payments places this provider in the 55th percentile of 59 interventional pain medicine providers in Pennsylvania.
See all interventional pain medicine providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tizanidine Hcl | 15 | $46 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in State College
- Keith ZoraState College$386
- Michael FishmanLebanon$670K
- David ProvenzanoSewickley$198K
- Michael FarrellPittsburgh$23K
- Farshad RashidianWest Chester$19K
- Chad MetzgerDarby$14K
- Jorge Rivero-BecerraPittsburgh$12K
- James BresnahanSpringfield$12K
- Jonathan SchollIndiana$11K
- Nathan MaltezosWest Chester$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.